Heparin in Interventional Radiology: A Therapy in Evolution

ABSTRACT

Interventional radiology techniques made possible by the antithrombotic properties of heparin have revolutionized treatment for a myriad of disorders. Newer low-molecular-weight heparins (LMWHs) offer several advantages over unfractionated heparin (UFH), especially in chronic settings. They are increasing in popularity for use during vascular procedures. However, LMWH shares limitations with UFH such as heterogeneity, nonspecificity, and induction of thrombocytopenia. These drawbacks have led to a search for the next generation of antithrombotic agents. Homogeneous drugs targeting specific coagulation cascade molecules are now available. The number of alternative anticoagulant drug combinations presents clinicians with a confusing array of choices. The strengths and weaknesses of UFH, LMWH, and direct antithrombin agents are presented. The promising future of LMWH and hirudins is discussed.

KEYWORDS

Heparin - low-molecular-weight heparin - interventional radiology - hirudin - bivalirudin - anticoagulation

REFERENCES

• 1 de Feyter P J, van den Brand M, Laarman G J et al.. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up.  Circulation. 1991;  83 927-936
• 2 Grayburn P A, Willard J E, Brickner M E, Eichhorn E J. In vivo thrombus formation on a guidewire during intravascular ultrasound imaging: evidence for inadequate heparinization.  Cathet Cardiovasc Diagn. 1991;  23 141-143
• 3 Bittl J A, Ahmed W H. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.  Am J Cardiol. 1998;  82 50P-56P
• 4 Swanson N, Hogrefe K, Stephens Lloyd A, Gershlick A. Current perspectives on British use of adjunctive therapies during coronary interventions.  Int J Cardiol. 2001;  79 119-125 discussion 126-117
• 5 Fareed J, Hoppensteadt D A, Bick R L. Management of thrombotic and cardiovascular disorders in the new millennium.  Clin Appl Thromb Hemost. 2003;  9 101-108
• 6 Rabenstein D L. Heparin and heparan sulfate: structure and function.  Nat Prod Rep. 2002;  19 312-331
• 7 Mason H R, Nowak R A, Morton C C, Castellot Jr J J. Heparin inhibits the motility and proliferation of human myometrial and leiomyoma smooth muscle cells.  Am J Pathol. 2003;  162 1895-1904
• 8 Hirsh J, Warkentin T E, Shaughnessy S G et al.. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.  Chest. 2001;  119 64S-94S
• 9 Mammen E F. Clinical relevance of antithrombin deficiencies.  Semin Hematol. 1995;  32 2-6 , discussion 7
• 10 Opal S M. Therapeutic rationale for antithrombin III in sepsis.  Crit Care Med. 2000;  28 S34-S37
• 11 Ohman E M, Harrington R A, Cannon C P, Agnelli G, Cairns J A, Kennedy J W. Intravenous thrombolysis in acute myocardial infarction.  Chest. 2001;  119 253S-277S
• 12 Choo J K, Kereiakes D J. Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.  J Thromb Thrombolysis. 2001;  11 235-246
• 13 Hirsh J, Weitz J I. New antithrombotic agents.  Lancet. 1999;  353 1431-1436
• 14 Weitz J I, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.  J Clin Invest. 1990;  86 385-391
• 15 Talbot M. Biology of recombinant hirudin (CGP 39393): a new prospect in the treatment of thrombosis.  Semin Thromb Hemost. 1989;  15 293-301
• 16 Fareed J, Walenga J M, Leya F et al.. Some objective considerations for the use of heparins and recombinant hirudin in percutaneous transluminal coronary angioplasty.  Semin Thromb Hemost. 1991;  17 455-470
• 17 Markwardt F. Hirudin and derivatives as anticoagulant agents.  Thromb Haemost. 1991;  66 141-152
• 18 Maraganore J M, Bourdon P, Jablonski J, Ramachandran K L, Fenton II J W. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.  Biochemistry. 1990;  29 7095-7101
• 19 Heras M, Chesebro J H, Penny W J, Bailey K R, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.  Circulation. 1989;  79 657-665
• 20 Agnelli G, Pascucci C, Cosmi B, Nenci G G. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.  Thromb Haemost. 1990;  63 204-207
• 21 de Swart C A, Nijmeyer B, Roelofs J M, Sixma J J. Kinetics of intravenously administered heparin in normal humans.  Blood. 1982;  60 1251-1258
• 22 Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans.  Acta Med Scand. 1963;  173 619-630
• 23 Bjornsson T D, Wolfram K M, Kitchell B B. Heparin kinetics determined by three assay methods.  Clin Pharmacol Ther. 1982;  31 104-113
• 24 Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin.  Scand J Haematol. 1971;  8 216-222
• 25 Levine M N, Hirsh J, Gent M et al.. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.  Arch Intern Med. 1994;  154 49-56
• 26 Raschke R A, Reilly B M, Guidry J R, Fontana J R, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care” nomogram. A randomized controlled trial.  Ann Intern Med. 1993;  119 874-881
• 27 Popma J J, Ohman E M, Weitz J, Lincoff A M, Harrington R A, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention.  Chest. 2001;  119 321S-336S
• 28 Frydman A M, Bara L, Le Roux Y, Woler M, Chauliac F, Samama M M. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg.  J Clin Pharmacol. 1988;  28 609-618
• 29 Briant L, Caranobe C, Saivin S et al.. Unfractionated heparin and CY 216: pharmacokinetics and bioavailabilities of the antifactor Xa and IIa effects after intravenous and subcutaneous injection in the rabbit.  Thromb Haemost. 1989;  61 348-353
• 30 Bratt G, Tornebohm E, Widlund L, Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.  Thromb Res. 1986;  42 613-620
• 31 Matzsch T, Bergqvist D, Hedner U, Ostergaard P. Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers.  Thromb Haemost. 1987;  57 97-101
• 32 Handeland G F, Abildgaard U, Holm H A, Arnesen K E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin.  Eur J Clin Pharmacol. 1990;  39 107-112
• 33 Boneu B, Caranobe C, Cadroy Y et al.. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit.  Semin Thromb Hemost. 1988;  14 18-27
• 34 Caranobe C, Barret A, Gabaig A M, Dupouy D, Sie P, Boneu B. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits.  Thromb Res. 1985;  40 129-133
• 35 Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance.  Thromb Haemost. 1987;  58 932-935
• 36 Tie M L, Koczwara B. Radiology interventions in patients receiving low molecular weight heparin: timing is critical.  Australas Radiol. 2001;  45 313-317
• 37 Kereiakes D J, Kleiman N S, Fry E et al.. Dalteparin in combination with abciximab during percutaneous coronary intervention.  Am Heart J. 2001;  141 348-352
• 38 Hettiarachchi R J, Smorenburg S M, Ginsberg J, Levine M, Prins M H, Buller H R. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.  Thromb Haemost. 1999;  82 947-952
• 39 Sciumbata T, Caretto P, Pirovano P et al.. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival.  Invasion Metastasis. 1996;  16 132-143
• 40 Vlodavsky I, Mohsen M, Lider O et al.. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.  Invasion Metastasis. 1994;  14 290-302
• 41 Albada J, Nieuwenhuis H K, Sixma J J. Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.  Circulation. 1989;  80 935-940
• 42 Nieuwenhuis H K, Albada J, Banga J D, Sixma J J. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin.  Blood. 1991;  78 2337-2343
• 43 College of American Pathologists .Coagulation (Comprehensive) Survey. Set CG2-B. Northfield, IL; College of American Pathologists 1999
• 44 Cloft H J, Jensen M E, Kallmes D F, Dion J E. Arterial dissections complicating cerebral angiography and cerebrovascular interventions.  AJNR Am J Neuroradiol. 2000;  21 541-545
• 45 Gladwell T D. Bivalirudin: a direct thrombin inhibitor.  Clin Ther. 2002;  24 38-58
• 46 Ducas J, Chan M C, Miller A, Kashour T. Immediate protamine administration and sheath removal following percutaneous coronary intervention: a prospective study of 429 patients.  Catheter Cardiovasc Interv. 2002;  56 196-199
• 47 Viaro F, Dalio M B, Evora P R. Catastrophic cardiovascular adverse reactions to protamine are nitric oxide/cyclic guanosine monophosphate dependent and endothelium mediated: should methylene blue be the treatment of choice?.  Chest. 2002;  122 1061-1066
• 48 Protamine sulfate antiheparin agents. In: McEvoy GK LK, Welsh OH et al AHFS Drug Information. Bethesda, MD; American Society of Health-System Pharmacists 1999: 1265-1267
• 49 Caplan S N, Berkman E M. Letter: protamine sulfate and fish allergy.  N Engl J Med. 1976;  295 172
• 50 Stewart W J, McSweeney S M, Kellett M A, Faxon D P, Ryan T J. Increased risk of severe protamine reactions in NPH insulin-dependent diabetics undergoing cardiac catheterization.  Circulation. 1984;  70 788-792
• 51 Burrows R F. Haematological problems in pregnancy.  Curr Opin Obstet Gynecol. 2003;  15 85-90
• 52 Greer I A. Exploring the role of low-molecular-weight heparins in pregnancy.  Semin Thromb Hemost. 2002;  28(suppl 3) 25-31
• 53 Levine M N, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment.  Chest. 2001;  119 108S-121S
• 54 The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 parients with acute ischaemic strike. Interantional Stroke Trial Collaborative Group.  Lancet. 1997;  349 1569-1581
• 55 Shammas N W, Lemke J H, Dippel E J et al.. In-hospital complications of peripheral vascular interventions using unfractionated heparin as the primary anticoagulant.  J Invasive Cardiol. 2003;  15 242-246
• 56 Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation.  N Engl J Med. 1994;  330 956-961
• 57 Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators.  N Engl J Med. 1997;  336 1689-1696
• 58 Milkovich G, Gibson G. Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention.  Am J Health Syst Pharm. 2003;  60 S15-S21
• 59 Blankenship J C, Balog C, Sapp S K et al.. Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials.  Catheter Cardiovasc Interv. 2002;  57 476-483
• 60 Applegate R J, Grabarczyk M A, Little W C et al.. Vascular closure devices in patients treated with anticoagulation and IIb/IIIa receptor inhibitors during percutaneous revascularization.  J Am Coll Cardiol. 2002;  40 78-83
• 61 Wysowski D K, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin.  N Engl J Med. 1998;  338 1774-1775
• 62 Tryba M, Wedel D J. Central neuraxial block and low molecular weight heparin (enoxaparine): lessons learned from different dosage regimes in two continents.  Acta Anaesthesiol Scand Suppl. 1997;  111 100-104
• 63 Brieger D, Solanki V, Gaynor M, Booth V, MacDonald R, Freedman S B. Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes.  Am J Cardiol. 2002;  89 1167-1170
• 64 MacDonald L A, Meyers S, Bennett C L et al.. Post-cardiac catheterization access site complications and low-molecular-weight heparin following cardiac catheterization.  J Invasive Cardiol. 2003;  15 60-62
• 65 Kaul S, Shah P K. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?.  J Am Coll Cardiol. 2000;  35 1699-1712
• 66 Bhatt D L, Lee B I, Casterella P J et al.. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.  J Am Coll Cardiol. 2003;  41 20-25
• 67 Khosla S, Kunjummen B, Guerrero M et al.. Safety and efficacy of combined use of low molecular weight heparin (enoxaparin, lovenox) and glycoprotein IIb/IIIa receptor antagonist (eptifibatide, integrelin) during nonemergent coronary and peripheral vascular intervention.  Am J Ther. 2002;  9 488-491
• 68 Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes.  J Am Coll Cardiol. 2003;  41 70S-78S
• 69 Allie D E, Lirtzman M D, Wyatt C H et al.. Bivalirudin as a foundation anticoagulant in peripheral vascular disease: a safe and feasible alternative for renal and iliac interventions.  J Invasive Cardiol. 2003;  15 334-342
• 70 Gould M K, Dembitzer A D, Doyle R L, Hastie T J, Garber A M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials.  Ann Intern Med. 1999;  130 800-809
• 71 Clagett G P, Reisch J S. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.  Ann Surg. 1988;  208 227-240
• 72 Nurmohamed M T, Rosendaal F R, Buller H R et al.. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis.  Lancet. 1992;  340 152-156
• 73 De Gregorio M A, Gimeno M J, Mainar A et al.. Mechanical and enzymatic thrombolysis for massive pulmonary embolism.  J Vasc Interv Radiol. 2002;  13 163-169
• 74 Jackson M R, Clagett G P. Antithrombotic therapy in peripheral arterial occlusive disease.  Chest. 2001;  119 283S-299S
• 75 Hingorani A, Gramse C, Ascher E. Anticoagulation with enoxaparin versus intravenous unfractionated heparin in postoperative vascular surgery patients.  J Vasc Surg. 2002;  36 341-345
• 76 Friedman H Z, Cragg D R, Glazier S M et al.. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty.  J Am Coll Cardiol. 1994;  24 1214-1219
• 77 Ellis S G, Roubin G S, Wilentz J, Douglas Jr J S, King III S B. Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty.  Am Heart J. 1989;  117 777-782
• 78 Koch K T, Piek J J, de Winter R J et al.. Safety of low dose heparin in elective coronary angioplasty.  Heart. 1997;  77 517-522
• 79 Kaluski E, Krakover R, Cotter G et al.. Minimal heparinization in coronary angioplasty: how much heparin is really warranted?.  Am J Cardiol. 2000;  85 953-956
• 80 Boccara A, Benamer H, Juliard J M et al.. A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty.  Eur Heart J. 1997;  18 631-635
• 81 Kereiakes D J, Grines C, Fry E et al.. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.  J Invasive Cardiol. 2001;  13 272-278
• 82 Karsch K R, Preisack M B, Baildon R et al.. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.  J Am Coll Cardiol. 1996;  28 1437-1443
• 83 Serruys P W, Herrman J P, Simon R et al.. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.  N Engl J Med. 1995;  333 757-763
• 84 Bittl J A, Strony J, Brinker J A et al.. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators.  N Engl J Med. 1995;  333 764-769
• 85 Kong D F, Topol E J, Bittl J A et al.. Clinical outcomes of bivalirudin for ischemic heart disease.  Circulation. 1999;  100 2049-2053
• 86 Topol E J, Bonan R, Jewitt D et al.. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty.  Circulation. 1993;  87 1622-1629
• 87 Carswell C I, Plosker G L. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.  Drugs. 2002;  62 841-870
• 88 Altmann D B, Racz M, Battleman D S et al.. Reduction in angioplasty complications after the introduction of coronary stents: results from a consecutive series of 2242 patients.  Am Heart J. 1996;  132 503-507
• 89 Fischman D L, Leon M B, Baim D S et al.. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators.  N Engl J Med. 1994;  331 496-501
• 90 Serruys P W, de Jaegere P, Kiemeneij F et al.. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group.  N Engl J Med. 1994;  331 489-495
• 91 Peterson E D, Lansky A J, Anstrom K J et al.. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database.  Am Heart J. 2000;  139 198-207
• 92 Narins C R, Hillegass Jr W B, Nelson C L et al.. Relation between activated clotting time during angioplasty and abrupt closure.  Circulation. 1996;  93 667-671
• 93 Ferguson J J, Dougherty K G, Gaos C M, Bush H S, Marsh K C, Leachman D R. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty.  J Am Coll Cardiol. 1994;  23 1061-1065
• 94 Schomig A, Neumann F J, Kastrati A et al.. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.  N Engl J Med. 1996;  334 1084-1089
• 95 Berger P B, Bell M R, Rihal C S et al.. Clopidogrel versus ticlopidine after intracoronary stent placement.  J Am Coll Cardiol. 1999;  34 1891-1894
• 96 Mishkel G J, Aguirre F V, Ligon R W, Rocha-Singh K J, Lucore C L. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting.  J Am Coll Cardiol. 1999;  34 1884-1890
• 97 Moussa I, Oetgen M, Roubin G et al.. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation.  Circulation. 1999;  99 2364-2366
• 98 Babalik E, Gulbaran M, Gurmen T, Ozturk S. Rescue coronary stenting with heparin-coated Jostents for failed thrombolysis in acute myocardial infarction.  Jpn Heart J. 2003;  44 335-345
• 99 Wallentin L, Goldstein P, Armstrong P W et al.. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.  Circulation. 2003;  108 135-142
• 100 Simoons M, Krzeminska-Pakula M, Alonso A et al.. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study.  Eur Heart J. 2002;  23 1282-1290
• 101 Baird S H, Menown I B, McBride S J, Trouton T G, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.  Eur Heart J. 2002;  23 627-632
• 102 Ibbotson T, Goa K L. Enoxaparin: an update of its clinical use in the management of acute coronary syndromes.  Drugs. 2002;  62 1407-1430
• 103 Ross A M, Molhoek P, Lundergan C et al.. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II).  Circulation. 2001;  104 648-652
• 104 Rebello S S, Kasiewski C J, Bentley R G et al.. Superiority of enoxaparin over heparin in combination with a GPIIb/IIIa receptor antagonist during coronary thrombolysis in dogs.  Thromb Res. 2001;  102 261-271
• 105 Wallentin L, Bergstrand L, Dellborg M et al.. Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction: the ASSENT Plus study.  Eur Heart J. 2003;  24 897-908
• 106 White H D. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial.  Am J Cardiol. 1998;  82 57P-62P
• 107 Cannon C P, McCabe C H, Diver D J et al.. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.  J Am Coll Cardiol. 1994;  24 1602-1610
• 108 Antman E M. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial.  Circulation. 1994;  90 1624-1630
• 109 Neuhaus K L, von Essen R, Tebbe U et al.. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK).  Circulation. 1994;  90 1638-1642
• 110 Neuhaus K L, Molhoek G P, Zeymer U et al.. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.  J Am Coll Cardiol. 1999;  34 966-973
• 111 Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction.  Circulation. 1995;  91 2132-2139
• 112 White H D, Aylward P E, Frey M J et al.. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.  Circulation. 1997;  96 2155-2161
• 113 Jacka M J, Clark A G. Intravenous heparin for cardiopulmonary bypass is an acute vasodilator.  J Clin Anesth. 2002;  14 179-182
• 114 Dager W E, White R H. Pharmacotherapy of heparin-induced thrombocytopenia.  Expert Opin Pharmacother. 2003;  4 919-940
• 115 Warkentin T E, Levine M N, Hirsh J et al.. Formation of heparin-induced thrombocytopenia IgG without thrombocytopenia: analysis of a clinical trial [abstract].  Blood. 1995;  86 537a
• 116 Warkentin T E. Heparin-induced skin lesions.  Br J Haematol. 1996;  92 494-497
• 117 Hong A P, Cook D J, Sigouin C S, Warkentin T E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia.  Blood. 2003;  101 3049-3051
• 118 Warkentin T E. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia New York; Marcel Dekker 2000: 43-80
• 119 Greinacher A, Volpel H, Janssens U et al.. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.  Circulation. 1999;  99 73-80
• 120 Greinacher A. Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. New York; Marcel Dekker 2000: 313-338
• 121 Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin.  Circulation. 1999;  100 1528-1532
• 122 Chen J L. Argatroban: a direct thrombin inhibitor for heparin-induced thrombocytopenia and other clinical applications.  Heart Dis. 2001;  3 189-198
• 123 Warkentin T E, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia New York; Marcel Dekker 2000: 211-244
• 124 Griffiths E, Dzik W H. Assays for heparin-induced thrombocytopenia.  Transfus Med. 1997;  7 1-11
• 125 Warkentin T E. Heparin-induced thrombocytopenia and the anesthesiologist.  Can J Anaesth. 2002;  49 S36-S49